EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis

Maria Livia Del Giudice iD, Sara Galimberti iD, Gabriele Buda

Hematological Oncology · 2024

DOI: 10.1002/hon.3270 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hematological Oncology, 2024. Verfasst von Maria Livia Del Giudice und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Amyloidosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Light chain amyloidosis is a rare disease caused by clonal plasma cells in the bone marrow generating an excessive amount of immunoglobulin light chains. These chains misfold and produce insoluble fibrils that deposit in various organs, including the heart, kidneys, liver, nervous system, and digestive tract. Life expectancy and symptoms during the course of the disease vary depending on which and how many organs are affected. Targeted plasma cell therapy has significantly advanced the clinical management of amyloidosis, with ongoing progress. However, current clinical studies are investigating innovative targets, drug combinations and treatment strategies to improve therapeutic outcomes by minimizing adverse effects and refining patient prognosis in these challenging hematological conditions. In this paper, we review the state of the art regarding the use of anti‐amyloid antibodies, as a revolutionary and innovative approach in the current scenario of amyloid treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light-chain AmyloidosisAmyloidosisHumansAntibodies, MonoclonalImmunoglobulin Light ChainsPlasma Cells

Stichwörter der Autor:innen

AL amyloidosisCAEL001anselamimabanti‐amyloid directed therapybirtamimabdaratumumab

Substanzen

Antibodies, MonoclonalImmunoglobulin Light Chains

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa, Italy.

ORCID-Profile: Maria Livia Del Giudice, Sara Galimberti

Zitieren

APA

Del Giudice, M. L., Galimberti, S., & Buda, G. (2024). Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis. Hematological Oncology. https://doi.org/10.1002/hon.3270

Vancouver

Del Giudice ML, Galimberti S, Buda G. Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis. Hematological Oncology. 2024. doi:10.1002/hon.3270

BibTeX
@article{DelGiudice2024,
  author = {Del Giudice, Maria Livia and Galimberti, Sara and Buda, Gabriele},
  title = {Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis},
  journal = {Hematological Oncology},
  year = {2024},
  doi = {10.1002/hon.3270}
}
Kostenlos starten →